Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Prednisolone acetate

Prednisolone acetate

Prednisolone acetate is a synthetic corticosteroid used to treat a variety of inflamatory conditions.
It has potent anti-inflammatory and immunosuppressant properties.
Prednisolone acetate is commonly used to manage eye and skin disorders, as well as neurological and joint inflammation.
Researchers can leverage PubCompare.ai's AI-powered platform to optimize their Prednisolone acetate research protocols, identify the most effective products and procedures, and streamline their workflow.
The intuitive tools and intelligent comparisons can help locate the best protocols from literature, preprints, and patents, while providing valuable AI-driven insigths to take your Prednisolone acetate studies to the next level.
Get started today and discvoer how PubCompare.ai can enhance your research.

Most cited protocols related to «Prednisolone acetate»

1
Automated SLE Case Identification Protocol
Cited 5 times
A priori, the authors decided to use as potential algorithm components the number of counts of the SLE ICD-9 code (710.0), keyword of “lupus” in the problem list, positive ANA, and ever use of medications frequently used in SLE such as antimalarials, systemic corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) (see below). These components were selected based upon SLE disease criteria and management combined with data accessible in the EHR. Subjects who were not classified as true SLE cases frequently had other autoimmune diseases with ICD-9 codes for these diseases. Multiple true SLE cases had an overlap syndrome (e.g. secondary Sjögren's syndrome or RA). We examined the exclusion of individuals with ICD-9 codes for other autoimmune diseases to assess whether potential SLE subjects who were not true SLE cases were appropriately excluded and also to ensure true SLE cases with overlap syndromes were not excluded. These exclusion criteria were selected during chart review of the training set.
Positive predictive values (PPVs) and sensitivity were calculated for every combination of ≥ 1, 2, 3, and 4 counts of the SLE ICD-9 code; a positive ANA, (titer ≥ 1:40 and titer ≥ 1:160); ever use of antimalarials, systemic corticosteroids, and disease-modifying antirheumatic drugs (DMARDs); and a keyword of “lupus” in the problem list using “and” or “or” between the criteria. PPVs were also calculated excluding ICD-9 codes for systemic sclerosis (SSc) (710.1) and dermatomyositis (DM) (710.3). All algorithms included individuals with at least one count of the SLE ICD-9 code. The PPV was calculated as the number of subjects who fit the algorithm and were confirmed cases on chart review divided by the total number of subjects who fit the algorithm. Sensitivity was calculated as the number of subjects who fit the algorithm and were confirmed cases on chart review divided by total number of confirmed cases. To “fit the algorithm,” the subject had to have available data for that particular algorithm's criteria. If an ANA was not checked at Vanderbilt, it was considered missing. The F-score, which is the harmonic mean of the PPV and sensitivity ([2 × PPV × sensitivity] / [PPV + sensitivity]), was calculated for all algorithms. The F-score is commonly used in informatics because it provides a single number to compare algorithms accounting for both PPV and sensitivity.
Antimalarials included in the medication search were “hydroxychloroquine,” “plaquenil,” “chloroquine,” “quinacrine,” and “aralen.” Oral and intravenous corticosteroids included were “cortisone acetate,” “hydrocortisone,” “Cortef,” “prednisone,” “dexamethasone,” “dexamethasone Intensol,” “decadron,” “prednisolone sodium phosphate,” “Pediapred,” “prednisone Intensol,” “methylprednisolone,” “Medrol,” “Medrol Dosepak,” “prednisolone,” “Orapred,” and “Prelone.” DMARDs included were “azathioprine,” “Imuran,” “methotrexate sodium,” “methotrexate,” “Trexall,” “mycophenolate mofetil,” “CellCept,” “mycophenolic acid,” “Myfortic,” “cyclophosphamide,” “Cytoxan,” “rituximab,” “Rituxan,” “etanercept,” “Enbrel,” “Enbrel Sureclick,” “adalimumab,” “Humira,” “Humira Pen,” “infliximab,” “Remicade,” “abatacept,” and “Orencia.”
Barnado A., Casey C., Carroll R.J., Wheless L., Denny J.C, & Crofford L.J. (2017). Developing Electronic Health Record Algorithms that Accurately Identify Patients with Systemic Lupus Erythematosus. Arthritis care & research, 69(5), 687-693.
Publication 2016
Abatacept Adalimumab Adrenal Cortex Hormones Antimalarials Antirheumatic Drugs, Disease-Modifying Aralen Autoimmune Diseases Azathioprine Cellcept Chloroquine Cortef Cortisone Acetate Cyclophosphamide Cytoxan Dermatomyositis Dexamethasone Enbrel Etanercept Humira Hydrocortisone Hydroxychloroquine Hypersensitivity Imuran Infliximab Lupus Vulgaris Medrol Methotrexate Methotrexate Sodium Methylprednisolone Mycophenolate Mofetil Mycophenolic Acid Myfortic Orencia Pharmaceutical Preparations Plaquenil Prednisolone prednisolone sodium phosphate Prednisone Quinacrine Remicade Rituxan Rituximab Sjogren's Syndrome Syndrome Systemic Scleroderma
2
Subretinal Delivery of rAAV2/5 in Dogs
Cited 4 times
Subretinal injections of rAAV2/5 carrying 3 different promoter constructs driving the GFP reported gene were performed under general anesthesia following previously published procedures.21 , 36 (link) A total of volume of 150 μl of the viral vector solution was delivered under direct visualization with an operating microscope via a transvitreal approach without vitrectomy using a Retinaject subretinal injector (SurModics Inc., Eden Prairie, MN). Visualization of the fundus was achieved with either a Machemer magnifying vitrectomy lens (OMVI; Ocular Instruments Inc., Bellevue, WA), or a vitreoretinal surgery contact lens (Acrivet Vit.Lens; Acrivet, Salt Lake City, UT). Several concentrations of each of the rAAV preparations were injected to determine the lowest titers capable of achieving sufficient expression of GFP in the targeted PRs (see titers in Table 1). As previous reports from our group have shown that subretinal injection of 150 μl of isotonic sodium chloride solution is safe and does not cause any structural alterations in the dog,36 (link), 37 (link) no virus-free vehicle controls were included in the current study. At the time of the injection it was noted whether a subretinal bleb was formed, and its location and extent were recorded on a diagram of the animal’s fundus (Figure 2A). Failed subretinal injections caused by either a sub-RPE injection, or by reflux into the vitreous, were also recorded. An anterior chamber paracentesis was immediately performed after the injection to prevent any increase in intraocular pressure, and a subconjunctival injection of 4 mg of triamcinolone acetonide was done in each eye.
Ophthalmic examinations, including biomicroscopy, indirect ophthalmoscopy, and fundus photography (Figs 2B1–2, C1–2) were conducted on a regular basis throughout the injection-termination time interval. Postoperative topical medication included application of atropine sulfate 1% drops once daily for 6 days, and prednisolone acetate 1% drops twice daily for 18 days. Systemic antibiotics (amoxicillin trihydrate/clavulanate potassium 20 mg/kg) were given orally twice daily for 1 week, and prednisolone oral solution (0.5 mg/kg) was administered twice daily for 5 days, followed by once daily for 1 week. Animals that showed signs of ocular inflammation after the completion of this initial treatment received a second subconjunctival injection of triamcinolone, oral administration of prednisolone, with or without topical application of prednisolone acetate 1%, and atropine sulfate 1%. In one case where improvement did not occur in one eye after the second round of treatment (Table 1; dog E1050), euthanasia was performed and eyes collected.
Beltran W.A., Boye S.L., Boye S.E., Chiodo V.A., Lewin A.S., Hauswirth W.W, & Aguirre G.D. (2010). rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters. Gene therapy, 17(9), 1162-1174.
Publication 2010
Administration, Oral Aftercare Amox clav Animals Antibiotics Chambers, Anterior Cloning Vectors Contact Lenses Euthanasia Eye Figs General Anesthesia Genes Inflammation Kenacort A Lens, Crystalline Microscopy Ophthalmoscopy Paracentesis Pharmaceutical Preparations Physical Examination Prednisolone prednisolone acetate Saline Solution Slit Lamp Sodium Chloride Sulfate, Atropine Tonometry, Ocular Triamcinolone Acetonide Virus Vision Vitrectomy Vitreoretinal Surgery
3
Trabectome and Phaco-AIT Outcomes
Cited 4 times
Subjects were enrolled from the Trabectome Study Group database,7 (link) a postmarket surveillance requirement for Neomedix, and divided into phakic patients who had only trabectome-mediated AIT or combined phacoemulsification with AIT (phaco-AIT). Data for this study were collected with institutional review board approval, in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act.
This prospective interventional cohort included all phakic patients with a diagnosis of glaucoma (with or without visually significant cataract), who had 12 months of follow-up. Anterior chamber angles in all patients were graded by Shaffer grade (SG),8 the most commonly used classification system in which ‘0’ to ‘slit’ represents a totally or partially closed angle with potential for angle closure that is present or very likely, ‘1’ an angle width of 10° (very narrow) and closure potential that is probable, ‘2’ representing 20° and possible potential for closure, ‘3’ standing for 20° to 45° with unlikely closure and grade ‘4’ indicating a wide open angle and improbable potential for angle closure. Subjects were excluded if they had missing preoperative IOP data or end-stage visual field (VF) damage.
The indication for AIT alone in phakic eyes consisted of IOP above target with progressive glaucoma on maximally tolerated medical or laser therapy. All surgeons were recommended to follow the standard postoperative protocol consisting of 1% pilocarpine four times per day for 1 month then three times per day for 1 month, 1% prednisolone acetate four times per day for 1 week to be tapered by one drop each week and a fourth or third generation fluoroquinolone four times per day for 1 week. Glaucoma medications could be continued as deemed necessary to achieve target pressures. Deviations from this protocol were allowed at the clinician's discretion and not monitored.
We converted visual acuities to logarithm of the minimum angle of resolution (logMAR). The indication for phaco-AIT consisted of a visually significant cataract with at least 0.4 logMAR (20/50 Snellen) visual brightness acuity testing and the need to lower IOP or the number of glaucoma medications. VF status was categorised as early, moderate or advanced by individual glaucoma specialists based on the most recent Humphrey VF exams (Carl Zeiss Meditec AG, Jena, Germany). All patients had a comprehensive slit lamp and ophthalmoscopy exam prior to surgery.
The major outcome measures included IOP, number of glaucoma medications, and need for secondary glaucoma surgery. Each hypotensive agent in an eye drop was counted as a glaucoma medication. Pilocarpine and oral carbonic anhydrase inhibitors were also counted as a glaucoma medication. We used the Wilcoxon test to compare IOP and number of medications within each group and between groups, and the Mann–Whitney test and χ2 test to compare continuous and categorical variables between groups, respectively. All statistical analyses were performed using R.9 Statistical significance was set at p<0.05. Continuous variables were expressed as mean±SD. We created scattergrams to illustrate individual outcomes and survival plots using a Kaplan–Meier survival analysis. Success was defined as a final IOP <21 mm Hg and a >20% reduction from baseline without further surgery. We analysed survival rates by SGs with the log-rank test.
Bussel I.I., Kaplowitz K., Schuman J.S, & Loewen N.A. (2014). Outcomes of ab interno trabeculectomy with the trabectome by degree of angle opening. The British Journal of Ophthalmology, 99(7), 914-919.
Publication 2014
Antihypertensive Agents Carbonic Anhydrase Inhibitors Cataract Chambers, Anterior Diagnosis Ethics Committees, Research Eye Fluoroquinolones Glaucoma Laser Therapy Operative Surgical Procedures Ophthalmic Solution Ophthalmoscopy Patients Phacoemulsification Pharmaceutical Preparations Pilocarpine prednisolone acetate Slit Lamp Specialists Surgeons Visual Acuity Visual Field Tests
4
Therapeutic Penetrating Keratoplasty for Fungal Keratitis
Cited 4 times
The study was approved by the Institutional Ethics Committee and followed the tenets of the Declaration of Helsinki. Out of a total of 1661 cases of fungal keratitis treated between January 2008 and December 2010, 198 (11.9%) consecutive patients underwent therapeutic penetrating keratoplasty (ThPK) at tertiary eye care center and were included in the study. Data collected included demographics, microbiology of ulcers, surgical details, such as graft size, details of donor tissue, duration of follow-up, and information on recurrent keratitis, such as time of recurrence, clinical features, and management of recurrent keratitis.
The standard practice pattern at the institute for the management of keratitis is described here briefly. All eyes diagnosed to have infection on their first visit to the clinic, irrespective of their past diagnosis and treatment, underwent a routine microbiological evaluation. The diagnosis of fungal keratitis was made after a clinical slit lamp examination, potassium hydroxide (KOH) mount, and smear examination. Following a microbiological confirmation on smears and/or culture, antifungal treatment was instituted comprising of topical natamycin 5% suspension every hourly and oral ketoconazole twice a day. If the corneal ulcer deteriorated (defined as increase in size of the infiltrate and exudates in the anterior chamber) or did not show evidence of improvement on periodic follow-up on third or fourth visit on clinical examination, ThPK was considered. All patients underwent a B-scan ultrasonography at the time of initial visit and before corneal transplantation to exclude spread of infection into the posterior segment.
ThPK was performed under either a peribulbar block or general anesthesia. Intraoperatively, care was taken to size the graft 0.5–1 mm more than the area of the infiltrate in its widest dimensions. In a routine ThPK, after removal of the diseased cornea, anterior chamber angle and iris surface were irrigated carefully with saline to remove any exudates and hypopyon and careful inspection was done at the edges of the host to ensure that the area of infiltrate was completely excised. In eyes with total corneal infiltrate, peritomy was done to inspect the sclera of any contiguous spread and part of infected sclera (as much as feasible to preserve the angle anatomy) was included in the trephination. Corneal grafts were secured with 16–24 interrupted 10–0 nylon sutures.
At the time of ThPK, the infected corneal button was divided into two parts. One part of the button was sent in a dry bottle for microbiological evaluation. In the microbiology facility, the dry corneal button was split into four under laminar flow and inoculated in blood agar, Sabouraud's dextrose agar, brain heart infusion, and non-nutrient agar. The second half was sent in formalin 1% for histopathological analysis.
The postoperative care comprised of frequent topical instillation of antifungal agents and oral ketoconazole for 2 weeks. Assessment was made for any recurrence during the first two postoperative weeks and initiation of topical corticosteroids (prednisolone acetate 1%) 4 to 6 hourly was done only after a period of 10–14 days only when the eye was noted to have no evidence of residual or recurrent infection on clinical slit lamp examination. In cases when recurrence was suspected, corticosteroids were deferred; and topical and oral antifungals were continued. Topical and oral antiglaucoma medications were added in the postoperative period in those with a raised intraocular pressure.
In cases with suspected recurrence of infection on clinical examination, corneal scrapings were taken whenever possible, examined as wet mounts with KOH, and subjected to fungal culture and strain identification. The finding of fungal filaments from any of the above examinations served as confirmation of fungal recurrence. Recurrence of fungal infection was managed with medical treatment with antifungals and/or surgical intervention in the form of anterior chamber wash or repeat therapeutic keratoplasty in some cases.
The software Origin v 7.0 (OriginLab Corporation, Northampton, MA, USA) was used to perform the statistical analysis. Normality of the continuous data and homoscedasticity were evaluated using Shapiro–Wilk and Levene tests, respectively. Mean (± standard deviation) and median (along with interquartile range, IQR) were used to describe the parametric and nonparametric data, respectively. Categorical data were described in proportions. Kaplan–Meier survival analysis was performed to estimate the probability of graft survival following ThPK. Cox proportional hazards regression analysis was done to evaluate the risk factors of graft failure. The recurrence rate after ThPK and the presence of different risk factors were compared with Chi-square analysis. A P value of <0.05 was considered statistically significant.
Mundra J., Dhakal R., Mohamed A., Jha G., Joseph J., Chaurasia S, & Murthy S. (2019). Outcomes of therapeutic penetrating keratoplasty in 198 eyes with fungal keratitis. Indian Journal of Ophthalmology, 67(10), 1599-1605.
Publication 2019
5
Topical Nepafenac vs. Prednisolone for Post-Vitrectomy
Cited 3 times
The study protocol adhered to the tenets of the Declaration of Helsinki. Approval for the trial was taken from the local Ethics Committee and all the participants signed a written informed consent. A total of 80 eyes of 76 patients were investigated in this study.
All eyes that underwent TSV between January 2009 to December 2010, for macular hole, epiretinal membrane, vitreomacular traction, and vitreous hemorrhage with attached retina on a USG B-scan, were included in the study. Cases having retinal detachments, those that required port conversion and suturing of port, re-surgery, pre-existing uveitis, those who had received intravitreal triamcinolone or anti vascular endothelial growth factor (VEGF) injections within three months of surgery, and cases requiring silicone oil for tamponade or buckling were excluded. Patients requiring cataract surgery along with vitrectomy were also excluded.
The participants were randomized to the postoperative topical nepafenac (0.1%) group or topical prednisolone acetate (1%) group in a double-masked fashion by a computer-generated randomization schedule. Cases receiving nepafenac formed Group 1 (n = 40) and cases receiving topical prednisolone acetate formed Group 2 (n = 40).
All cases were operated on the Alcon constellation vision system by the same surgeon (M.N). All cases completed the three-month follow up. The subjects were asked to grade the ocular pain on the visual analog scale.[17 (link)18 (link)] The VAS consisted of a 10-cm line, with 0 on one end representing no pain and 10 on the other representing the worst pain ever experienced. A subject marked on this line to indicate the severity of his or her pain experience. The VAS was filled up by the patients on Day 1, Day 30, and Day 90. Intraocular inflammation was graded on each visit by an investigator, masked to the study group (S.L.), using the Standardization of Uveitis Nomenclature Working Group grading classification. According to this classification, less than one cell (in a 1 mm2 field illuminating the anterior chamber) is taken as grade 0, 1 to 5 cells as grade 0.5, 6 to 15 cells grade 1, 16 to 25 cells as grade 2, 26 to 50 cells as grade 3, and more than 50 cells as grade 4. Lid edema was graded as follows: Minimal swelling with lid creases visible was grade 1, moderate swelling with skin creases affected was grade 2, marked swelling when eye lids could be opened actively was grade 3, and extreme swelling when eyelids could not be opened actively was grade 4. Conjunctival chemosis was taken as grade 1 if it involved 30% of the conjunctiva, grade 2 if it involved 30-70% of the conjunctiva, and grade 3 if it involved 70-100% of the conjunctiva. Conjunctival hyperemia was graded as grade 0 for no hyperemia, grade 1 for sectoral engorgement of vessels, grade 2 for diffuse engorgement, and grade 3 for significant engorgement.
Best corrected visual acuity was obtained on Snellen Visual acuity charts at each visit.
Subjects self-administered the drops in both the groups, with group 1 receiving nepafenac (Nevanac, Alcon Laboratories, Inc. Fort Worth, Texas, USA) three times in a day for six weeks and group 2 receiving Pred Forte (Allergan, Inc. Irvine, CA, U.S.A.) beginning six times a day for week one and four times a day till week four, two times a day for week five, and once a day for week six. All the patients received prophylactic antibiotics for four weeks and atropine sulfate 1% HS for a week. All the patients also received a diclofenac sodium 100 mg suppository preoperatively and diclofenac sodium 50 mg tablet postoperatively twice per day, for five days.
The descriptive statistics were calculated for case characteristics. Group comparisons were performed with the Wilcoxon rank-sum test, using the two-sided analysis. P < 0.05 was considered significant. Snellen visual acuity was converted to logMAR units for analysis purposes.
Nagpal M., Lambat S., Mehrotra N., Paranjpe G., Yadav H, & Bhardwaj S. (2014). Topical nepafenac 0.1% alone versus prednisolone acetate 1% as postoperative anti-inflammatory agents in small gauge vitrectomy. Indian Journal of Ophthalmology, 62(5), 606-609.
Publication 2014

Most recents protocols related to «Prednisolone acetate»

1
DMEK Surgery Postoperative Care
Not available on PMC !
For the first week after DMEK surgery, patients received dexamethasone dihydrogen phosphate disodium 1.0 mg/ml and gentamicin sulfate 5.0 mg/ml eye drops five times daily and prednisolone acetate 10.0 mg/ml eye drops (Inflanefran forte, Allergan, Dublin, Ireland), five times daily. Additionally, patients received pilocarpine 20.0 mg/g eye drops twice daily until complete resolution of intraocular 20.0% SF 6 gas, respectively. After the first month, only prednisolone acetate 10.0 mg/ml eye drops were continued. These were tapered by one drop every month to a maintenance dose of once daily for life.
Lohmann T., Baumgarten S., Kürten D., Prinz J., Plange N., Walter P, & Fuest M. (2024). Effects of graft detachment on the central corneal thickness after uncomplicated Descemet membrane endothelial keratoplasty. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.
Publication 2024
2
Glucocorticoid-induced Ocular Hypertension
OH was induced in ten eyes, five eyes G1, and five eyes G3. Topical prednisolone acetate drops (10 mg/mL Prednefrin Forte Eye drops, Allergan, Brazil) were used twice a day to raise and maintain elevated IOP. This was associated with weekly subconjunctival injections of 0.5 mL betamethasone acetate (Celestone Chronodose, 3 + 3 mg/mL disodium phosphate, Schering-Plough, Mexico) [12 (link), 13 ] in the right eye for 5 weeks, with the left eye used as the control.
Evangelho K.D., Cifuentes-González C., Rojas-Carabali W., Vivero-Arciniegas C.D., Cañas-Arboleda M., Salguero G., Ramírez-Santana C, & de-la-Torre A. (2024). Early detection of optic nerve head changes using optical coherence tomography after using mesenchymal stromal cells as intravitreal therapy in rabbit models of ocular hypertension. Veterinary World, 17(2), 500-508.
Full text: Click here
Publication 2024
3
Phacoemulsification Technique for Cataract Extraction
Not available on PMC !
A 2.2 mm Clear Cut blade was used to make a transparent corneal incision (temporal or superotemporal). Using a Micro-Smooth ULTRA Infusion Sleeve and a Kelman-style curved 45 phacoemulsification tip, an 80e90% deep central vertical groove can be made along the entire length of the nucleus.
A side port manipulator should be placed at the base of the left wall when performing phacoemulsification, and the phacoemulsification tip should be placed at the base of the right wall.
The lateral groove of the right heminucleus is subsequently employed for the insertion of the Kelman-style tip and side port manipulator. Each of the left and right heminuclei contains two different quadrants.
The phacoemulsification tip effectively captures all four quadrants, bringing them towards the central region of the pupil, and then fragmenting them through the use of a chopper against the phacoemulsification tip, utilizing the conventional machine settings designed for the extraction of torsional quadrants.
The topical administration of prednisolone acetate eyedrops at a concentration of 1% was initiated for the initial 1 week hourly administration, followed by administration every three hours for an additional 1 week, and decreased to every 6 h administration for a duration of 10 days.
Topical adminstration of broad spectrum antibiotics (moxifloxacin) with the same protocol of prednisolone acetate.
Mahdy M., Zeyada H., & Mansour Y.H.M.I. (2024). Phacoemulsification in Cases of Zonular Weakness Using In Situ Nuclear Disassembly without Nuclear Rotation. Al-Azhar International Medical Journal /Al-Azhar International Medical Journal, 5(2).
Publication 2024
4
Post-Operative Management of Anterior Chamber Gas
Postoperative medication included topical prednisolone acetate 1% or dexamethasone 1% five times daily in tapering dosage over at least 12 months and unpreserved topical antibiotic eye drops with ofloxacin for two weeks, as well as preservative-free artificial tears (five times a daily). In addition, in the two cases with gas in the anterior chamber Pilocarpine 2% eye drops were applied three times a day for as long as the gas covered the lower edge of the pupil, and the patients were instructed to maintain a strict supine postoperative position for at least for three days, with only bathroom privileges and continuous intraocular pressure (IOP) monitoring. 20Due to the high-risk constellation in these cases, systemic immunosuppression was prescribed, initially with cortisone and mycophenolate mofetil 1 gram twice daily, reduced to mycophenolate mofetil alone after 4 weeks. Immunosuppressive therapy was maintained for at least 1 year. One case with herpetic corneal disease received no immunosuppressive therapy, but long-term topical Ganciclovir and systemic Acyclovir and Prednisolone.
Schöneberger V., Tahmaz V., Matthaei M., Roters S., Schlereth S.L., Schaub F., Cursiefen C, & Bachmann B.O. (2024). Allogeneic limbo-deep anterior lamellar keratoplasty (Limbo-DALK)—A novel surgical technique in corneal stromal disease and limbal stem cell deficiency. PLOS ONE, 19(2), e0298241.
Full text: Click here
Publication 2024
5
Refractive Surgery Protocols: LASIK, PRK, SMILE
LASIK: Flaps were created to be 8.7–9 mm in diameter and 100 µm thick. They were completed using the FS200 (Alcon Laboratories, Inc., Fort Worth, TX, USA) femtosecond laser. The WaveLight EX500 Excimer Laser System (Alcon Laboratories, Inc., Fort Worth, TX, USA) was the excimer laser used for corneal ablation. Ablation zones were 6.5 mm with a transition zone of up to 9.0 mm. Post-operative treatment included topical ofloxacin or moxifloxacin (0.3 or 0.5%, respectively) and prednisolone acetate 1%. The steroid was to be used every hour for the remainder of the day following the procedure. The steroid and antibiotic were then used q.i.d. for 1 week.
PRK: The corneal epithelium was removed after 20 s application of 18% alcohol. This was followed by ablation using WaveLight EX500 Excimer Laser System (Alcon Laboratories, Inc., Fort Worth, TX, USA) with an ablation a zone of 6.5 mm central ablation and up to a 9 mm transitional zone. If the ablation depth went beyond 65 µm, then Mitomycin C 0.02% was given for approximately 20 s. Post-operatively, an Acuvue Oasys (Johnson & Johnson Vision Care, Inc., Jacksonville, FL, USA) bandage contact was applied for five to seven days, until epithelialization was complete. Topical moxifloxacin 0.5% was prescribed for four drops daily for a total of seven days, and prednisolone acetate was prescribed at four drops daily for one month. After one month, fluorometholone 0.1% drops were applied three times per day for three weeks and then tapered: b.i.d. for another three weeks and then q.d. for three weeks.
SMILE: The VisuMax 500 kHz femtosecond laser (Carl Zeiss Meditec, Jena, Germany) was used to create the lenticule, which was preset to be either 6.0 mm with a 0.5 mm transition zone for toric treatments or 6.5 mm for spherical treatment. This was completed by using a laser energy of 125 nJ, with cap thickness and diameter inputted at 120 µm and 7.5 mm, respectively. A 3.5 mm superior incision was used at a 90-degree meridian with a side-cut angle of 90 degrees. The measurements for lenticular spot separation, side cut, cap cut, and cap angle were 3.7 µm, 2.0 µm, 3.8 µm, and 2.0 µm, respectively. Post-operative drops included topical ofloxacin 0.3% or moxifloxacin 0.5% and prednisolone acetate 1%. The antibiotic was dosed q.i.d. for 1 week, and the steroid was tapered: q.i.d. for one week, b.i.d. for one week, and q.d. for two weeks.
Moshirfar M., Omidvarnia S., Christensen M.T., Porter K.B., Theis J.S., Olson N.M., Stoakes I.M., Payne C.J, & Hoopes P.C. (2024). Comparative Analysis of Corneal Higher-Order Aberrations after Laser-Assisted In Situ Keratomileusis, Photorefractive Keratectomy, and Small Incision Lenticule Extraction with Correlations to Change in Myopic Q-Value and Spherical Equivalent with and without Astigmatism. Journal of Clinical Medicine, 13(7), 1906.
Full text: Click here
Publication 2024

Top products related to «Prednisolone acetate»

1
Pred forte by Abbvie
Sourced in United States, Ireland
Pred Forte is a prescription eye drop solution that contains the active ingredient prednisolone acetate. It is a corticosteroid medication used to reduce inflammation in the eye.
2
Vigamox by Alcon
Sourced in United States, Ireland, Germany, Canada
Vigamox is an ophthalmic solution used in the treatment of bacterial conjunctivitis. It contains the active ingredient moxifloxacin hydrochloride, a broad-spectrum fluoroquinolone antibiotic.
3
Cravit by Santen
Sourced in Japan, Ireland, China, United States
Cravit is a laboratory equipment product. It is used for conducting scientific experiments and analyses.
4
Prednisolone by Merck Group
Sourced in United States, Japan, United Kingdom, Italy, Germany, Sao Tome and Principe, Denmark
Prednisolone is a synthetic corticosteroid used in the Merck Group's laboratory equipment. It functions as an anti-inflammatory and immunosuppressant agent.
5
Prednisolone acetate by Abbvie
Sourced in United States, Ireland
Prednisolone acetate is a synthetic corticosteroid medication used in various laboratory applications. It serves as a potent anti-inflammatory and immunosuppressant agent.
6
Levofloxacin eye drops by Santen
Sourced in Japan, United States, China
Levofloxacin eye drops is a topical ophthalmic solution containing the antibiotic levofloxacin. It is intended for the treatment of bacterial conjunctivitis.
7
Tobramycin by Alcon
Sourced in United States, Belgium
Tobramycin is a broad-spectrum aminoglycoside antibiotic used for the treatment of various bacterial infections. It is a laboratory product designed for research and clinical applications.
8
Levofloxacin by Santen
Sourced in Japan, China
Levofloxacin is a broad-spectrum antibiotic agent that belongs to the fluoroquinolone class of antibacterial drugs. It is a synthetic, bactericidal agent that inhibits the activity of bacterial DNA gyrase and topoisomerase IV, which are essential for bacterial cell division and DNA replication.
9
Milli q system by Merck Group
Sourced in United States, Germany, France, United Kingdom, Italy, Morocco, Spain, Japan, Brazil, Australia, China, Belgium, Ireland, Denmark, Sweden, Canada, Hungary, Greece, India, Portugal, Switzerland
The Milli-Q system is a water purification system designed to produce high-quality ultrapure water. It utilizes a multi-stage filtration process to remove impurities, ions, and organic matter from the input water, resulting in water that meets the strict standards required for various laboratory applications.
10
Methanol by Thermo Fisher Scientific
Sourced in United States, United Kingdom, China, Germany, Belgium, Canada, France, India, Australia, Portugal, Spain, New Zealand, Ireland, Sweden, Italy, Denmark, Poland, Malaysia, Switzerland, Macao, Sao Tome and Principe, Bulgaria
Methanol is a colorless, volatile, and flammable liquid chemical compound. It is commonly used as a solvent, fuel, and feedstock in various industrial processes.

More about "Prednisolone acetate"